Novo Nordisk's CEO Mike Doustdar went on CNBC to announce his company might buy other companies. Groundbreaking stuff. A pharmaceutical giant worth over $400 billion just realized that when you make a drug that prints money, other companies will try to make the same drug. Doustdar's solution? Diversification. The business equivalent of a teenager saying he's "thinking about his options."
The weight-loss market got crowded. Eli Lilly showed up with Zepbound. Suddenly Novo's Wegovy isn't the only game in town. So Doustdar needs deals. He needs M&A opportunities. He needs to tell CNBC something that sounds like strategy but really means "we're sweating."
Retail traders heard "deals beyond obesity" and started Googling what else Novo makes. They found insulin. Groundbreaking discovery, guys. A Danish pharmaceutical company makes diabetes medication. Someone call the SEC.
The funniest part? Novo spent years as the only company that could make fat people skinny with a weekly injection, and now that there's competition, the CEO is on cable news talking about diversification like he's running a f*cking lemonade stand that just discovered winter exists. "We're considering opportunities." Translation: we had one product doing all the work and now we're panic-buying our way into relevance.
Doustdar wants you to know Novo isn't just about obesity anymore. They're thinking bigger. Broader. They're a healthcare company, damn it, not just the Ozempic people. Except everyone knows them as the Ozempic people. That's the brand now.
The stock chart doesn't care about diversification speeches on CNBC, but retail traders will buy the dip anyway because a CEO said words on television.
Photo by on Unsplash
Leave a Comment